211
Participants
Start Date
May 31, 2010
Primary Completion Date
November 30, 2011
NVA237
50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
Tiotropium
18µg capsules for inhalation, delivered via HandiHaler®
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kurume
Novartis Investigative Site, Ōnojō
Novartis Investigative Site, Yanagawa
Novartis Investigative Site, Asahikawa
Novartis Investigative Site, Obihiro
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Himeji
Novartis Investigative Site, Takarazuka
Novartis Investigative Site, Yabu
Novartis Investigative Site, Inashiki-gun
Novartis Investigative Site, Naka-gun
Novartis Investigative Site, Sashima-gun
Novartis Investigative Site, Morioka
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kochi
Novartis Investigative Site, Uji
Novartis Investigative Site, Matsusaka
Novartis Investigative Site, Sendai
Novartis Investigative Site, Nagaoka
Novartis Investigative Site, Nagaoka
Novartis Investigative Site, Kasaoka
Novartis Investigative Site, Tsuyama
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Sakai
Novartis Investigative Site, Sayama
Novartis Investigative Site, Takatsuki
Novartis Investigative Site, Saitama
Novartis Investigative Site, Shimotsuka-gun
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Nakano-ku
Novartis Investigative Site, Ohta-ku
Novartis Investigative Site, Yamagata
Novartis Investigative Site, Ube
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY